Suppr超能文献

一名有急性支架血栓形成病史的患者在停用双联抗血小板治疗后发生极晚期支架血栓形成。

Very late stent thrombosis after dual antiplatelet therapy discontinuation in a patient with a history of acute stent thrombosis.

作者信息

Bhatt Snehal H, Hauser Thomas H

机构信息

Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Boston, MA 02115, USA.

出版信息

Ann Pharmacother. 2008 May;42(5):708-12. doi: 10.1345/aph.1K647. Epub 2008 Apr 1.

Abstract

OBJECTIVE

To describe a case of very late stent thrombosis after dual antiplatelet discontinuation in a patient with a previous history of stent thrombosis.

CASE SUMMARY

A 62-year-old man with a history of coronary artery disease, multiple acute coronary syndromes requiring percutaneous coronary interventions with multiple stent placements, and acute stent thrombosis resulting in ST segment elevation myocardial infarction presented to the hospital with chest pain. The chest pain was not relieved by 4 sublingual nitroglycerin tablets. Five days prior to his presentation, the patient had been instructed to discontinue both aspirin and clopidogrel in preparation for a left ankle fusion procedure. He was taken to the cardiac catheterization laboratory where he was found to have thrombosis in a sirolimus-eluting stent placed more than 3 years ago. Thrombectomy and balloon angioplasty were performed, and the patient completed his hospital course without complications.

DISCUSSION

Stent thrombosis associated with drug-eluting stents is a complicated pathophysiologic phenomenon with multiple patient-, procedure-, and device-related factors. Application of these risk factors to quantify the risk of stent thrombosis as they apply to a single patient is unknown. Discontinuation of recommended dual antiplatelet therapy with aspirin plus a thienopyridine has been identified as a major risk factor for stent thrombosis, but the optimal duration of dual antiplatelet therapy remains unknown. Current recommendations suggest extending dual antiplatelet therapy beyond one year in patients with low bleeding risk.

CONCLUSIONS

Given the overall data at this time and the severity of stent thrombosis, it seems prudent to continue dual antiplatelet therapy with aspirin indefinitely plus a thienopyridine for at least one year, with continuation beyond one year on a case-by-case basis depending on the risks of in-stent thrombosis and bleeding. In patients with a low risk of bleeding, indefinite continuation of dual antiplatelet therapy may be reasonable.

摘要

目的

描述1例有支架血栓形成病史的患者在停用双联抗血小板治疗后发生极晚期支架血栓形成的病例。

病例摘要

一名62岁男性,有冠状动脉疾病史,多次急性冠状动脉综合征需行经皮冠状动脉介入治疗并置入多个支架,曾发生急性支架血栓形成导致ST段抬高型心肌梗死,因胸痛入院。4片舌下含服硝酸甘油未能缓解胸痛。在此次就诊前5天,患者因准备行左踝关节融合手术,遵医嘱停用了阿司匹林和氯吡格雷。他被送往心脏导管实验室,发现3年多前置入的西罗莫司洗脱支架内有血栓形成。行血栓切除术和球囊血管成形术,患者顺利完成住院疗程,无并发症发生。

讨论

与药物洗脱支架相关的支架血栓形成是一种复杂的病理生理现象,涉及多种与患者、手术及器械相关的因素。这些危险因素如何应用于量化单个患者发生支架血栓形成的风险尚不清楚。已确定停用推荐的阿司匹林加噻吩并吡啶双联抗血小板治疗是支架血栓形成的主要危险因素,但双联抗血小板治疗的最佳持续时间仍不清楚。目前的建议是,出血风险低的患者应将双联抗血小板治疗延长至1年以上。

结论

鉴于目前的总体数据以及支架血栓形成的严重性,对于出血风险低的患者,似乎谨慎的做法是无限期继续使用阿司匹林加噻吩并吡啶进行双联抗血小板治疗至少1年,并根据支架内血栓形成和出血的风险,逐例决定是否延长至1年以上。对于出血风险低的患者,无限期继续双联抗血小板治疗可能是合理的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验